Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Bavachalcone inhibits osteoclast differentiation through suppression of NFATc1 induction by RANKL.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Park CK;Park CK; Lee Y; Chang EJ; Lee MH; Yoon JH; Ryu JH; Kim HH
- Source:
Biochemical pharmacology [Biochem Pharmacol] 2008 Jun 01; Vol. 75 (11), pp. 2175-82. Date of Electronic Publication: 2008 Mar 21.
- Publication Type:
Journal Article; Research Support, Non-U.S. Gov't
- Language:
English
- Additional Information
- Source:
Publisher: Elsevier Science Country of Publication: England NLM ID: 0101032 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2968 (Electronic) Linking ISSN: 00062952 NLM ISO Abbreviation: Biochem Pharmacol Subsets: MEDLINE
- Publication Information:
Publication: Oxford : Elsevier Science
Original Publication: Oxford, New York [etc.] Paragamon Press.
- Subject Terms:
- Abstract:
Osteoclasts are cells that have a specialized role for bone resorption and are responsible for many bone diseases such as osteoporosis. As herbal products are invaluable sources in discovery of compounds for new therapies, we sought to identify compounds efficacious in suppressing osteoclastogenesis from medicinal plants that have been implicated for treatment of osteoporotic conditions. Bavachalcone was isolated from Psoralea corylifolia, and its effects on osteoclast differentiation were evaluated with primary cultures of osteoclast precursor cells. In addition, the molecular mechanism of action was investigated. Bavachalcone inhibited osteoclast formation from precursor cells with the IC(50) of approximately 1.5 microg ml(-1). The activation of MEK, ERK, and Akt by receptor activator of nuclear factor kappaB ligand (RANKL), the osteoclast differentiation factor, was prominently reduced in the presence of bavachalcone. The induction of c-Fos and NFATc1, key transcription factors for osteoclastogenesis, by RANKL was also suppressed by bavachalcone. In conclusion, bavachalcone inhibits osteoclastogenesis by interfering with the ERK and Akt signaling pathways and the induction of c-Fos and NFATc1 during differentiation. Our results suggest that bavachalcone may be useful as a therapeutic drug for bone resorption-associated diseases.
- Accession Number:
0 (Chalcones)
0 (Flavones)
0 (NFATC Transcription Factors)
0 (Nfatc1 protein, mouse)
0 (RANK Ligand)
0 (Tnfsf11 protein, mouse)
0 (bavachalcone)
EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
EC 2.7.11.24 (Extracellular Signal-Regulated MAP Kinases)
- Publication Date:
Date Created: 20080425 Date Completed: 20080613 Latest Revision: 20091119
- Publication Date:
20240829
- Accession Number:
10.1016/j.bcp.2008.03.007
- Accession Number:
18433733
No Comments.